EJNMMI Research

Table 2 Dosimetry of ⁶⁴Cu-NOTA-Trastuzumab (OLINDA)

From: A preliminary clinical trial to evaluate ⁶⁴Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer

Organ	Absorbed dose (mGv/MBq)
Organ	⁶⁴Cu-NOTA-Trastuzumab	⁶⁴Cu-DOTA-Trastuzumab [6]	[⁸⁹Zr]Trastuzumab [9]
Adrenals	0.005 ± 0.001	0.031 ± 0.004	0.80
Brain	0.009 ± 0.002	0.015 ± 0.003	0.39
Breasts	0.002 ± 0.000	0.020 ± 0.001	0.42
Gallbladder wall	0.006 ± 0.001	0.035 ± 0.008	0.86
LLI wall	0.000 ± 0.000	0.018 ± 0.002	0.58
Small intestine	0.001 ± 0.000	0.019 ± 0.001	0.57
Stomach wall	0.008 ± 0.002	0.024 ± 0.002	0.63
ULI wall	0.002 ± 0.000	0.022 ± 0.002	0.65
Heart wall	0.042 ± 0.008	0.340 ± 0.046	1.11
Kidneys	0.044 ± 0.009	0.103 ± 0.034	1.23
Liver	0.076 ± 0.007	0.237 ± 0.117	1.63
Lungs	0.034 ± 0.004	0.057 ± 0.070	0.59
Muscle	0.001 ± 0.000	0.023 ± 0.006	0.49
Ovaries	0.001 ± 0.000	0.018 ± 0.002	0.59
Pancreas	0.005 ± 0.001	0.032 ± 0.003	0.78
Red marrow	0.001 ± 0.000	0.017 ± 0.001	0.69
Osteogenic cells	0.001 ± 0.000	0.035 ± 0.001	0.79
Skin	0.001 ± 0.000	0.015 ± 0.001	0.34
Spleen	0.063 ± 0.010	0.142 ± 0.040	0.86
Thymus	0.003 ± 0.000	0.030 ± 0.002	0.57
Thyroid	0.000 ± 0.000	0.016 ± 0.001	0.43
Urinary	0.003 ± 0.001	0.023 ± 0.006	0.42
Uterus	0.001 ± 0.000	0.018 ± 0.002	0.58
Total body	0.004 ± 0.000	0.029 ± 0.004	0.55
Effective dose (mSv/MBq)	0.010 ± 0.001	0.036 ± 0.009	0.61

Back to article page